Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.76 |
| ▸ | MMP13 | P45452 | 20/20 | 0.76 |
| ▸ | MMP2 | P08253 | 1/20 | 0.76 |
| ▸ | MMP3 | P08254 | 1/20 | 0.76 |
| ▸ | MMP9 | P14780 | 1/20 | 0.76 |
| ▸ | MMP8 | P22894 | 1/20 | 0.76 |
| ▸ | MMP12 | P39900 | 1/20 | 0.76 |
| ▸ | MMP14 | P50281 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575324 | 0.98 | MMP1 (0.79) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL5139159 | 0.93 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL1080224 | 0.91 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL12076481 | 0.91 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7208011 | 0.91 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL27415619 | 0.89 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL7514521 | 0.88 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL5914586 | 0.87 | MMP1 (0.74) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7978660 | 0.87 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6869740 | 0.87 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796468-A2 | Antibodies to insulin-like growth factor I receptor | Pfizer Inc (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | MMP1 4431/4885MMP13 4056/4885MMP2 3651/4885 |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | MMP1 397/4885MMP13 203/4885MMP2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.